Destiny Pharma is an innovative pharmaceutical company focused on the development of novel medicines that represent a totally different approach to infectious disease.
These novel medicines are being developed to address the growing and unmet demand for prophylaxis and treatment of life-threatening drug-resistant bacteria, often referred to as “superbugs”.
Destiny Pharma’s XF Drug Platform is being developed to address existing and emerging multi-drug resistant microbial pathogens which cause infections within and outside of hospitals.
The lead drug XF-73 (exeporfinium chloride), is targeted for the Prevention of post-surgical staphylococcal infections. Staphylococcus aureus is a leading cause of hospital, bacterial infections, including methicillin-resistant S. aureus (MRSA) the most important and dangerous multi-drug resistant form of the bacteria. Traditional research has failed to fully address these problems. Destiny is pursuing revolutionary approaches to the prevention and treatment of this public health crisis.
The XF Drug platform offers a number of new anti-microbial drug product opportunities with a low potential for eliciting an Antibiotic Resistance response from a range of clinically important bacteria. The role of biofilm in perpetuating chronic infection is now becoming more recognised and drug products with the potential to act against biofilm-associated infections hold significant promise.
World Health Organisation:
“Antimicrobial resistance increases the costs of health care: When infections become resistant to first-line drugs, more expensive therapies must be used. A longer duration of illness and treatment, often in hospitals, increases health care costs as well as the economic burden on families and societies.”
“Antimicrobial resistance jeopardizes health care gains to society: The achievements of modern medicine are put at risk by antimicrobial resistance. Without effective antimicrobials for prevention and treatment of infections, the success of organ transplantation, cancer chemotherapy and major surgery would be compromised.”